Tezepelumab Improved Severe Asthma in Half of Patients
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab (Tezspire) than placebo, according to research presented at ATS 2022.
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab (Tezspire) than placebo, according to research presented at ATS 2022.
The FDA has issued an emergency use authorization for AstraZeneca’s Evusheld (tixagevimab and cilgavimab) to prevent COVID-19 in certain adults and children.
AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorization in the European Union for adults 18 and older.
Data from a late-stage trial on the cancer drug Imfinzi, in combination with chemotherapies, demonstrated improvement in survival of certain lung cancer patients, AstraZeneca Plc announced this week.
Read MoreNew data demonstrated that the maintenance combination asthma therapy, Symbicort (budesonide/formoterol fumarate dehydrate), provides a rapid, clinically significant bronchodilatory response.
Read More